Pharmacotherapy of premature ejaculation: a systematic review and network meta-analysis
- 382 Downloads
The purpose of the study was to conduct a systematic evaluation of the different general prescribed drugs for premature ejaculation (PE).
A systematic literature search of MEDLINE, Cochrane Central Register of Controlled Trials, and Web of Science for Systematic Reviews was performed on 1 March 2018. Intravaginal ejaculation latency time (IELT) was the main outcome. Analysis was performed under multivariate random-effects network model and efficacies of drugs were ranked with surface under the cumulative ranking (SUCRA) probabilities.
A total of 48 studies were reviewed and 40 of them were further enrolled into network meta-analysis. The majority of RCTs were of unclear methodological quality. Pooled evidence suggested that topical anaesthetic creams (TAs), tramadol, selective serotonin reuptake inhibitors (SSRIs), and phosphodiesterase type 5 inhibitors (PDE5is) are more effective at prolonging IELT comparing with placebo. TAs (90%) on demand (OD) and PDE5is plus SSRI (89.8%) had the highest SUCRA, which meant the most probable to be the most effective intervention.
We recommend the initial use of dapoxetine 30 mg OD for PE because it has been tested in largest and better designed clinical trials rather than it is more effective than the other drugs studied. TAs and tramadol 50 mg OD can be used as a viable alternative to oral treatment with SSRIs. PDE5is combined with SSRIs are more effective than SSRIs monotherapy but are also associated with more side effects. PDE5is OD can be recommended to PE patients with ED.
KeywordsSexual health Premature ejaculation Medical treatment Pharmacology of ejaculation
ZJ and XW: project development, data collection and management, manuscript writing and revising, data analysis; DY: data collection, data analysis and revising; HL: data collection, data analysis; KW: project design and development, data interpretation, manuscript editing and revising. All authors read and approved the final manuscript.
This article is supported by grants from 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZY2016104), Project of the Health and Family Planning Committee of Sichuan Province and The popularization and promotion of ureteroscopic technique in the treatment of upper urinary tract stones in primary hospitals (16PI294).
Compliance with ethical standards
Conflict of interest
The authors of this article as well as all the included studies declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent was obtained from all individual participants included in the study.
- 1.Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, Alexander J (2007) The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 51(3):816–823. https://doi.org/10.1016/j.eururo.2006.07.004 (discussion 824)CrossRefPubMedGoogle Scholar
- 2.Serefoglu EC, McMahon CG, Waldinger MD, Althof SE, Shindel A, Adaikan G, Becher EF, Dean J, Giuliano F, Hellstrom WJ, Giraldi A, Glina S, Incrocci L, Jannini E, McCabe M, Parish S, Rowland D, Segraves RT, Sharlip I, Torres LO (2014) An evidence-based unified definition of lifelong and acquired premature ejaculation: report of the second international society for sexual medicine ad hoc committee for the definition of premature ejaculation. J Sex Med 2(2):41–59. https://doi.org/10.1002/sm2.27 CrossRefGoogle Scholar
- 8.Martyn-St James M, Cooper K, Ren S, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, Hood C (2017) Phosphodiesterase-5 inhibitors for premature ejaculation: a systematic review and meta-analysis. Eur Urol Focus 3(1):119–129. https://doi.org/10.1016/j.euf.2016.02.001 CrossRefPubMedPubMedCentralGoogle Scholar
- 14.White IR (2009) Multivariate random-effects meta-analysis. Stata J 9(1):40–56Google Scholar
- 25.Novaretti JP, Pompeo AC, Arap S (2002) Selective serotonin re-uptake inhibitor in the treatment of premature ejaculation. Braz J Urol 28(2):116–122Google Scholar
- 29.Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S (2006) Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 368(9539):929–937. https://doi.org/10.1016/s0140-6736(06)69373-2 CrossRefPubMedGoogle Scholar
- 34.Dinsmore WW, Hackett G, Goldmeier D, Waldinger M, Dean J, Wright P, Callander M, Wylie K, Novak C, Keywood C, Heath P, Wyllie M (2007) Topical eutectic mixture for premature ejaculation (TEMPE): a novel aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 99(2):369–375. https://doi.org/10.1111/j.1464-410X.2006.06583.x CrossRefPubMedGoogle Scholar
- 39.Farnia V, Raisi F, Mohseni MG, Atharikia D, Ghafuri Z (2009) On-demand treatment of premature ejaculation with citalopram: a randomized double-blind study. Acta Med Iran 47(5):353–357Google Scholar
- 40.Buvat J, Tesfaye F, Rothman M, Rivas DA, Giuliano F (2009) Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 55(4):957–967. https://doi.org/10.1016/j.eururo.2009.01.025 CrossRefPubMedGoogle Scholar
- 41.Mathers MJ, Klotz T, Roth S, Lummen G, Sommer F (2009) Safety and efficacy of vardenafil versus sertraline in the treatment of premature ejaculation: a randomised, prospective and crossover study. Andrologia 41(3):169–175. https://doi.org/10.1111/j.1439-0272.2008.00910.x CrossRefPubMedGoogle Scholar
- 42.Dinsmore WW, Wyllie MG (2009) PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study. BJU Int 103(7):940–949. https://doi.org/10.1111/j.1464-410X.2009.08456.x CrossRefPubMedGoogle Scholar
- 43.McMahon C, Kim SW, Park NC, Chang CP, Rivas D, Tesfaye F, Rothman M, Aquilina J (2010) Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 7(1 Pt 1):256–268. https://doi.org/10.1111/j.1743-6109.2009.01560.x CrossRefPubMedGoogle Scholar
- 44.Carson C, Wyllie M (2010) Improved ejaculatory latency, control and sexual satisfaction when PSD502 is applied topically in men with premature ejaculation: results of a phase III, double-blind, placebo-controlled study. J Sex Med 7(9):3179–3189. https://doi.org/10.1111/j.1743-6109.2010.01913.x CrossRefPubMedGoogle Scholar
- 46.Gokce A, Demirtas A, Halis F, Ekmekcioglu O (2010) In vitro measurement of ejaculation latency time (ELT) and the effects of vardenafil on ELT on lifelong premature ejaculators: placebo-controlled, double-blind, cross-over laboratory setting. Int Urol Nephrol 42(4):881–887. https://doi.org/10.1007/s11255-010-9710-2 CrossRefPubMedGoogle Scholar
- 47.Gokce A, Halis F, Demirtas A, Ekmekcioglu O (2011) The effects of three phosphodiesterase type 5 inhibitors on ejaculation latency time in lifelong premature ejaculators: a double-blind laboratory setting study. BJU Int 107(8):1274–1277. https://doi.org/10.1111/j.1464-410X.2010.09646.x CrossRefPubMedGoogle Scholar
- 48.Bar-Or D, Salottolo KM, Orlando A, Winkler JV, Tramadol ODT Study Group (2012) A randomized double-blind, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of the tramadol orally disintegrating tablet for the treatment of premature ejaculation within less than 2 minutes. Eur Urol 61(4):736–743CrossRefGoogle Scholar
- 50.McMahon CG, Giuliano F, Dean J, Hellstrom WJ, Bull S, Tesfaye F, Sharma O, Rivas DA, Aquilina JW (2013) Efficacy and safety of dapoxetine in men with premature ejaculation and concomitant erectile dysfunction treated with a phosphodiesterase type 5 inhibitor: randomized, placebo-controlled, phase III study. J Sex Med 10(9):2312–2325. https://doi.org/10.1111/jsm.12236 CrossRefPubMedGoogle Scholar
- 52.Lee WK, Lee SH, Cho ST, Lee YS, Oh CY, Yoo C, Cho JS, Lee SK, Yang DY (2013) Comparison between on-demand dosing of dapoxetine alone and dapoxetine plus mirodenafil in patients with lifelong premature ejaculation: prospective, randomized, double-blind, placebo-controlled, multicenter study. J Sex Med 10(11):2832–2841. https://doi.org/10.1111/jsm.12287 CrossRefPubMedGoogle Scholar
- 53.Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy Ael N (2013) On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab J Urol 11(4):392–397. https://doi.org/10.1016/j.aju.2013.05.003 CrossRefPubMedPubMedCentralGoogle Scholar
- 55.Zhang X (2014) Combination of sertraline and sildenafil versus sertraline monotherapy in the treatment of acquired premature ejaculation without concomitant diseases. Androl-Open Access 03(1)Google Scholar
- 57.Kurkar A, Elderwy AA, Abulsorour S, Awad SM, Safwat AS, Altaher A (2015) A randomized, double-blind, placebo-controlled, crossover trial of “on-demand” tramadol for treatment of premature ejaculation. Urol Ann 7(2):205–210. https://doi.org/10.4103/0974-7796.150481 CrossRefPubMedPubMedCentralGoogle Scholar
- 61.Abu El-Hamd M, Abdelhamed A (2018) Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: a randomised placebo-controlled clinical trial. Andrologia. https://doi.org/10.1111/and.12829 CrossRefPubMedGoogle Scholar
- 62.Hamidi-Madani A, Motiee R, Mokhtari G, Nasseh H, Esmaeili S, Kazemnezhad E (2018) The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: a randomized double-blind placebo-controlled clinical trial. J Reprod Infertil 19(1):10–15PubMedPubMedCentralGoogle Scholar
- 63.Epstein DH, Preston KL, Jasinski DR (2006) Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol 73(1):90–99. https://doi.org/10.1016/j.biopsycho.2006.01.010 CrossRefPubMedPubMedCentralGoogle Scholar
- 64.Dechartres A, Boutron I, Trinquart L, Charles P, Ravaud P (2011) Single-center trials show larger treatment effects than multicenter trials: evidence from a meta-epidemiologic study. Ann Intern Med 155(1):39–51. https://doi.org/10.7326/0003-4819-155-1-201107050-00006 CrossRefPubMedGoogle Scholar